Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors

2.1 Asciminib (Scemblix, Novartis) is indicated for the 'treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation'.

2.2 The dosage schedule is available in the summary of product characteristics for asciminib.

2.3 The list price for asciminib is £4,050.37 for a 60‑tablet pack of 40‑mg tablets (excluding VAT; company submission).

2.4 The company has a commercial arrangement. This makes asciminib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.